A study to evaluate the hypothyroidism as a predictive clinical marker of better treatment response to sunitinib therapy in patients with metastatic renal cell carcinoma.

Trial Profile

A study to evaluate the hypothyroidism as a predictive clinical marker of better treatment response to sunitinib therapy in patients with metastatic renal cell carcinoma.

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Dec 2015

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 10 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top